

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10571311	
	Filing Date		2006-03-09	
	First Named Inventor	WURST		
	Art Unit	1617		
	Examiner Name	SOROUSH		
Attorney Docket Number		27234U		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1						

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.

Receipt date: 04/20/2011

Application Number	10571311	10571311 - GAU: 1617
Filing Date	2006-03-09	
First Named Inventor	WURST	
Art Unit	1617	
Examiner Name	SOROUSH	
Attorney Docket Number	27234U	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

/A.S./	1	BIBERGER, C., et al., "Efficacy and safety of ciclesonide compared with budesonide in asthma patients: a randomized 12-week study", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1486.	<input type="checkbox"/>
	2	BOULET, L-P., et al., "Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1505.	<input type="checkbox"/>
	3	BUNDSCHUH, D.S., et al., "[1013] Pre-clinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide", Oral Presentation: New developments in inhaled corticosteroid therapy (2:45 PM - 4:45 PM) Sunday, September 23, 2001, 2:45 PM, Hall 4/5.	<input type="checkbox"/>
	4	DEROM, E., et al., "Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients", Oral presentation at the 11th Annual Congress of the European Respiratory Society (ERS); September 22-26, 2001; Berlin, Germany, Eur Respir J., 2001; 18: Abstract 1015.	<input type="checkbox"/>
	5	ENGELSTÄTTER, R., et al., "Comparative study in asthma patients treated with inhaled ciclesonide (80 µg or 320 µg once daily) or budesonide (200 µg twice daily) for 12 weeks", Presented as a poster at the 99th International Conference of the American Thoracic Society (ATS); May 16-21, 2003; Seattle, Wash., Am J Respir Crit Care Med., 2003; 167: Abstract A1511.	<input type="checkbox"/>
	6	HANSEL, T., et al., "Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients", Eur Respir J 2003; 22 Suppl 45: 410. Plus poster presented at the 13th Annual Congress of the European Respiratory Society, 2003; September 27-October 1; Vienna; Abstract no. P2639.	<input type="checkbox"/>
	7	KANNIESS, F., et al., "Effect of Inhaled Ciclesonide on Airway Responsiveness to Inhaled AMP, the Composition of Induced Sputum and Exhaled Nitric Oxide in Patients with Mild Asthma", Pulmonary Pharmacology & Therapeutics, (2001), 14, 141-147, © 2001 Academic Press.	<input type="checkbox"/>
	8	SZEFLER, S.J., Deputy Editor, "Early intervention for childhood asthma: Inhaled glucocorticoids as the 'preferred' medication", J Allergy Clin Immunol 1998; 102: 719-721, © 1998 by Mosby, Inc.	<input type="checkbox"/>
	9	UKENA, D., et al., "Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study", Eur Respir J 2003; 22 (Suppl. 45): 411s, Plus poster presented at the 13th Annual Congress of the European Respiratory Society, 2003; September 27-October 1; Vienna; Abstract no. P2640.	<input type="checkbox"/>
↓	10	WAGENER, J.S., et al., "Inhaled steroids in children: Risks versus rewards", The Journal of Pediatrics, Volume 132, Number 3, Part 1, Pages 381-383, © 1998 by Mosby, Inc.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Receipt date: 04/20/2011

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10571311	10571311 - GAU: 1617
Filing Date	2006-03-09	
First Named Inventor	WURST	
Art Unit	1617	
Examiner Name	SOROUSH	
Attorney Docket Number	27234U	

EXAMINER SIGNATURE

Examiner Signature	/Ali Soroush/	Date Considered	09/10/2011
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.